IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 1822 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   Article in PDF (435 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Introduction
   Treatment
   Medical Therapies
   Adjunctive Therapies
   New Drug Deliver...
   Conclusion
   References
   Article Tables

 Article Access Statistics
    Viewed18901    
    Printed292    
    Emailed14    
    PDF Downloaded1101    
    Comments [Add]    
    Cited by others 8    

Recommend this journal

 


 
REVIEW ARTICLE
Year : 2010  |  Volume : 76  |  Issue : 3  |  Page : 231-238

Topical treatment in vitiligo and the potential uses of new drug delivery systems


1 University Institute of Pharmaceutical, Sciences-UGC Center of Advanced Studies, Panjab University, Chandigarh, India
2 Skin Clinic, Indra Nagar, Lucknow, India

Date of Web Publication4-May-2010

Correspondence Address:
Om Prakash Katare
University Institute of Pharmaceutical Sciences-UGC, Center of Advanced Studies, Panjab University, Chandigarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.62961

Rights and Permissions

  Abstract 

Vitiligo is a psychologically devastating condition. Topical therapy is employed as first-line treatment in localized vitiligo. Currently, several topical agents are available in many forms viz. methoxsalen (solution and cream), trioxsalen (solution), corticosteroids (gel, cream, ointment and solution) and calcineurin inhibitors (ointment and cream). Although topical therapy has an important position in vitiligo treatment, side-effects or poor efficacy affect their utility and patient compliance. Novel drug delivery strategies can play a pivotal role in improving the topical delivery of various drugs by enhancing their epidermal localization with a concomitant reduction in their side-effects and improving their effectiveness. The current review emphasizes the potential of various phospholipid based carriers viz. liposomes, transferosomes, ethosomes, lipid emulsions, solid lipid nanoparticles and organogels in optimizing and enhancing the topical delivery of anti-vitiligo agents, whilst reducing the side effects of drugs commonly used in its topical treatment.


Keywords: Novel drug delivery, phospholipid-based carriers, topical therapies, vitiligo


How to cite this article:
Garg BJ, Saraswat A, Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprol 2010;76:231-8

How to cite this URL:
Garg BJ, Saraswat A, Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprol [serial online] 2010 [cited 2017 Nov 25];76:231-8. Available from: http://www.ijdvl.com/text.asp?2010/76/3/231/62961



  Introduction Top


Vitiligo is an acquired idiopathic, dermatological disorder characterized by well-circumscribed milky white macules devoid of identifiable melanocytes. These asymptomatic white macules can be psychologically extremely damaging, even leading to attempted suicide in some cases. [1] It affects approximately 1% of the world's population and approximately 3-4% of the Indian population. [2],[3] The most common sites of involvement are the face (24.5%), neck (18.8%), and scalp (11.2%). [4]

The exact etiology of vitiligo is unknown. It is believed that vitiligo is a polygenic trait and that a convergence theory combining elements of different etiological theories across a spectrum of expression is the most accurate etiology. [5]


  Treatment Top


In general, topical monotherapy is indicated for mild-to-moderate vitiligo. Current treatment options for vitiligo include medical, surgical and adjunctive treatments. [6],[7]

Medical treatment targets the immune system and helps to arrest the spread of depigmentation. In cases of stable vitiligo, repigmentation can be achieved by dermatosurgical techniques and adjunctives includes use of cosmetics. Both surgical and medical treatment have their own limitations. Adjunctive can only cover the patch and be used along with surgical or medical treatments.


  Medical Therapies Top


The best studied and most commonly used medical treatment options are corticosteroids, psoralens and depigmenting agents.

Corticosteroids: Topical steroids are often first-line therapy, especially in children or for localized disease. Moderately potent to potent topical corticosteroids are used. [8],[9] However, vitiligo requires prolonged use of these agents, often much longer than the usual "safe" recommended periods of use for inflammatory dermatoses. This results in significant, therapy-limiting side-effects like atrophy, hypertrichosis, peri-lesional hypopigmention etc. It is obvious that currently available dosage formulations do not provide site-specific drug delivery.

Phototherapy: Phototherapy is one of the oldest forms of treatment of vitiligo and remains the bedrock of vitiligo therapy even today. Out of three [5-MOP (bergapten), 4, 5, 8-trimethylpsoralen (TMP) and 8-MOP (methoxsalen)] different types of psoralens, 8-MOP is the most commonly used. Topical psoralen photochemotherapy (PUVA) is often used for people with limited disease (affecting less than 20% of the body). It is also used for children 12 years and older, who have localized patches for vitiligo. [10] Severe sunburn, blistering and abnormally dark repigmentation are major potential side-effects of topical PUVA therapy. This is due to the uncontrolled photo- reaction of psoralen with ultra-violet A irradiation in the epidermis because drug is freely available from currently available dosage formulations, for reaction on surface after topical application. [11] In recent years, narrow-band UVB (NB-UVB, 311 nm) has become the preferred phototherapy for vitiligo. [12],[13]

Calcium modulators: Recently, calcium modulators, the vitamin D3 analogues (calcipotriol and tacalcitol), have also been tried in the treatment of vitiligo. [14] Defective calcium transport has been shown in melanocytes and keratinocytes harvested from patients with vitiligo Further, vitamin D3 has been shown to activate melanin synthesis. [15] There are contradictory reports of their efficacy in vitiligo, both as monotherapy and in combination with both PUVA and NB-UVB phototherapy. The most common adverse effect of calcipotriol is lesional irritation and potential hypercalcemia if applied in quantity > 100mg in a week. So, controlled delivery can potentially deliver better results by modifying currently available dosage formulations, minimizing both systemic absorption and local irritation.

Calcineurin inhibitors: Calcineurin inhibitors (tacrolimus, pimecrolimus) are some of the newest topical drugs in dermatology. [16],[17] However, tacrolimus and pimercrolimus are effective only in vitiligo lesions on the head and neck region. [18] The main difficulty with topical calcineurin inhibitors, and one that is probably responsible for lack of efficacy in non-facial vitiligo, is their high molecular weight. This precludes efficient delivery of the drug at the level of the basal cells, since the stratum corneum allows very poor absorption of any molecules over "500Da" in weight. [19] This has recently been proved by an elegant study where greatly enhanced repigmentation with pimecrolimus was achieved by using it after performing microdermabrasion on the lesional skin. [20] Hence, carrier mediated drug delivery can substantially increase their effectiveness bypassing the stratum corneum barrier and delivering these drugs in adequate concentration to the melanocytes and keratinocytes.


  Adjunctive Therapies Top


Depigmentation: Depigmentation is a more drastic form of treatment, when vitiligo is extensive i.e. vitiligo universalis. Depigmentation involves fading the rest of the skin on the body to match the already white areas by using permanent melanocytotoxic agents such as Monobenzyl ether of hydroquinone cream (Benoquin; ). The major side-effect includes irritant dermatitis but rarely limits therapy. [21] A more recent method of depigmentation utilizes topical 4-methoxyphenol (4-MP) and the Q-switched ruby laser (QSR). [22]

Sunscreens: People who have vitiligo are more susceptible to sunburn and long term photodamage. To prevent sun-induced darkening of the surrounding normal skin, broad spectrum high protection factor sunscreens (SPF15-30) which provide protection from both UVB and UVA light should be used.

Cosmetics: Camouflage is often used to "cover" affected areas. This may be practical for patients that have minimal disease or segmental disease. [23],[24],[25] Many brands of dyes Dermacolor; (Kryolan) and Dermablend; (L'Oreal) are available in India.


  New Drug Delivery Systems Top


In contrast to the traditional oral route, topical drug delivery for vitiligo has many advantages. It bypasses all major organ systems like GIT, liver, kidney etc. there by avoiding many issues of adverse effects, bioavailability etc. Nevertheless, topical application of drugs is not a simple matter. The major hurdle in producing the desired therapeutic action is the inability of the existing dosage forms like gels, lotions, creams and ointments to serve or deliver what is required, where it is required. Currently, material selection and designing of these dosage forms fails to account for the physiological and structural aspects of skin (e.g. the tough cornified stratum corneum as barrier to drug transport), while the drug related issues of high molecular weight, skin penetration, release parameters and stability are not properly addressed. [26],[27] The complex lipid and cellular structure within the cornified layer of intra-follicular epidermis, composed of ceramides, cholesterol and free fatty acids contributes to the impermeability of skin. [28] These reasons have been responsible for using systemic route for many a potential drug candidate for primary skin manifestations, whereas the topical route could have been the more appropriate choice. For example, the systemic delivery of potentially hazardous drugs like psoralen and corticosteroids through oral route has been in practice for vitiligo and many other skin diseases, as their topical products are either not very effective, or produce too many local adverse effects. [29],[30]

The failure of topical conventional dosage forms is mainly accounted for by poor penetration and inability to place the drug molecules at the desired site of action for a prolonged period without allowing systemic absorption. Also the conventional dosage forms are unable to provide the protection to the normal tissues leading to "innocent bystander" side effects like dermal atrophy with corticosteroids. The drug also needs to be shielded from the local metabolic milieu of the skin, so that it is protected from breakdown into inert or toxic metabolites. Inactive metabolites would curtail drug action, requiring repeated application and toxic metabolites can produce unacceptable adverse effects. Further, in a traditional approach, the major drawback is the non-consideration of the real requirement of the drug molecule at the particular site for desired action. In this regard, a tailored system is needed to transport and target the molecule in the most effective manner. In a nut shell, all the problems associated with the conventional formulations, suggest that modifications and innovations are required in the way topical therapy is administered.

Drug-carrier systems

Recently, a variety of materials and methods are being used to create some very exquisitely built carrier systems. [31],[32] Some of these systems are mentioned in [Table 1].

These carriers, with their own specificities, have attracted the formulations based on requirement and application of their field of work. The last decade has seen a phenomenal growth in the use of phospholipid-structured carriers in topical delivery. Simultaneously, it has been seen that the other carriers mentioned in [Table 1] are also useful for oral and parenteral drug delivery.

Topical drug delivery systems

Phospholipid-structured carriers would be the vehicle of choice for topical delivery for vitiligo because optimized topical delivery employing these phospholipid-structured carrier systems was seen due to improved profile (pharmacokinetic and pharmacodynamic) of the chosen drug molecules for various skin diseases. [33],[34],[35] This was due to various reasons discussed below:

  • Skin-friendly: The carrier systems composed of phospholipids (e.g., lecithin) are shown to improve the skin condition by virtue of their nonirritating, non-sensitizing, and nontoxic, moisture retentive nature. Lecithin is a naturally occurring substance that is considered a very good skin conditioner furnishing excellent repair of the skin's barrier as well.
  • Transport across skin: Enhanced drug penetration across the tough and dense lamellar lipidic matrix of stratum corneum may be achieved as a result of favorable hydro-lipophilic microenvironment of the drug molecules, which greatly influences the partitioning of the drug and facilitates skin transport. Simultaneous modification in the barrier function of stratum corneum due to incorporation of phospholipids (into skin layers) also favors the transport of drug across skin. The problems associated with poor skin penetration of tacrolimus, pimecrolimus due to their large molecule more than 500 Da (as per '500 Dalton rule'), can be improved using the carrier approach.
  • Super-solvent effect: Phospholipid-based carrier systems, by virtue of the amphiphilicity and supramolecular association, provide a super-solvent effect, which keeps the active medicament in molecularly dispersed state so that the transfer across the skin is facilitated. These have ability to deliver both hydrophilic as well as lipophilic drugs. Carriers can provide super-solvent effect by keeping methoxsalen in dispersed state which has a crystalline nature otherwise.
  • Prolonged action: Increased drug-localization in the skin strata is expected by the formation of micro-reservoirs, which may help in producing prolonged local action and reduced systemic effects. This would be of tremendous value in topical corticosteroids, minimizing dermal atrophy and telangiectasia whilst allowing less frequent application. In a chronic condition like vitiligo, it has been seen that patient compliance reduces markedly over time. Topical agents that have to be applied only once a day or perhaps even less frequently would increase patient compliance significantly.
  • Pronounced action: Enhanced drug action, besides a prolonged presence, is another benefit that may be attributed to the presence of the therapeutic molecules at or near the target site. The drug in the proposed carrier may produce better drug-target interactions. In case of vitiligo, after using carrier mediated delivery of methoxsalen, reaction with UV-light will only occur at or near melanocytes (not on skin surface).Which would help in reducing phototoxic side effects.
  • Improved patient compliance: Better patient acceptability with the carrier-based product is also an outcome due to the skin-moisturizing effect, which helps in keeping skin in the active state. And the favorable rheological properties of these systems, in contrast to greasy ointments, add to the patient acceptance. Simultaneously reduction in side effects may improve patient compliance.
  • Dose reduction and improved safety: The safety of the drug is also expected to be increased as the enhanced drug action may allow reduction in the number of molecules to elicit the desired pharmacotherapeutic effect. And also the hydrating effect in the lipid-rich environment reduces the irritant effect of the molecules which is otherwise cyto-destructive. Carrier-based delivery can reduce the dose of calcipotriol in vitiligo treatment, which would help in minimizing its local and systemic side effects and improve its utility.
  • Targeting to desired site: Drug molecules can be targeted to the desired site by modifying the physicochemical nature of vesicular systems. The best known example is Doxil TM in cancer chemotherapy, which is pegylated (polyethylene glycol coated) liposome-encapsulated form of doxorubicin. This ligand-binding promotes efficient drug uptake into cells and enhances efficacy. [36] In vitiligo therapy, although at present no ligand-based carrier systems are available, it is theoretically possible that this could be the most effective and safe method of delivery actives if melanocytes can specifically be made to take up the topically applied agents.
  • Enhance stability: Vesicular systems enhance the stability of poorly stable drug like dithranol, tretinoin, etc. The proposed mechanism behind this is the entrapment of drug within the lamellae of the vesicle, making it unavailable to open atmosphere or to light.
Phospholipid-structured carriers

Vesicular approaches


Liposomes: Liposomes are microscopic, fluid-filled pouches whose walls are made of layers of phospholipids. Liposomes were first produced in England in 1961 by Alec D. Bangham but the potential value of liposomes for topical therapy was first introduced by Mezei and Gulasekharam. Cholesterol may be included to improve bilayers characteristics of liposomes; increasing microviscosity of the bilayers, reducing permeability of the membrane to water soluble molecules, stabilizing the membrane and increasing rigidity of the vesicles. Psorisome TM , a liposomal-gel version of dithranol produced in our laboratory is one such example. Further, results of several studies [Table 2] indicate that liposomes were useful for drug delivery in vitiligo and other dermatological disorders. [37],[38],[39],[40]

Transferosomes: Cevc, et al, introduced the first generation of elastic vesicles, referred to as transferosomes. These self-optimized aggregates, with the ultraflexible membrane, are able to deliver the drug reproducibly either into or through the skin with high efficacy. [41],[42],[43] The better skin penetration ability of these elastic vesicles in comparison to liposome is supported by various studies [Table 2].

Ethosomes: Ethosomes are lipid-based elastic vesicular systems embodying ethanol in relatively high concentrations which enhance the topical drug delivery. The presence of ethanol prolongs the physical stability of the ethosomes with respect to liposomes. The enhanced delivery of actives incorporated in the ethosomes [Table 2] can be ascribed to the interactions between ethosomes and skin lipids. That may open the new pathways due to the malleability and fusion of ethosomes with skin lipids, which results in the penetration of drug into deeper skin layers. [44],[45],[46]

Non-vesicular approaches

Lipid emulsion: Lipid emulsions are thermodynamically stable, isotropic, low viscosity colloidal dispersions consisting of micro-domains of oil and/or water, stabilized by an interfacial film of alternating surfactant and cosurfactant molecules. The incorporation of lipids improves the physical stability of emulsion by forming a mono- or multi-layer around the dispersed liquid droplets which reduces the interfacial tension or increases the droplet-droplet repulsion. As topical vehicle, lipid emulsions [Table 2] have potential to enhance the permeation and form local cargo or micro-reservoirs in the deeper skin layers to provide localized action. [47],[48],[49]

Lecithin organogels (LOs): LOs are micro-structured biocompatible gels, which are chiefly comprised of phospholipids (lecithins) and appropriate organic liquids. LOs are simple in the sense that they are formed spontaneously by virtue of their thermodynamic stability. A number of therapeutic agents have been incorporated in the LOs for their facilitated transport across the skin and improve their therapeutics. [50],[51] In the wake of the commercial availability of one class of LOs, known as PLOs (Pluronic lecithin organogels) as template vehicle for topical delivery of many therapeutic agents, the importance of research in this area has increased manifold [Table 2].

Solid lipid nanoparticles (SLNs) : They are submicron sized carriers for controlled and targeted drug delivery. Nanoparticles are diverse both in shape and composition. SLNs combine the advantages of different colloidal carriers, for instance - emulsions and liposomes. Particulate systems like nanoparticles have been used as a physical approach to alter and improve the pharmacokinetic and pharmacodynamic properties of various types of drug molecules. [52],[53],[54]


  Conclusion Top


A number of drugs [Table 3] are available in the market, which have achieved improved efficacy and safety after incorporating the active agents in carrier systems. Therefore, putting new life into erstwhile discarded drug molecules by transforming them into novel formulations can serve as viable and cost effective alternative to the expensive and time consuming search of newer chemical entities. In recent times, new excipients, refined processing techniques, and a better knowledge of the physicochemical properties of vehicles and drugs have led to the development of new delivery systems that have the potential to re-invent the topical treatments of vitiligo. The authors of this review hope that further research with enhanced collaboration between pharmaceutical and dermatology researchers will bring this hitherto untapped potential to fruition.

 
  References Top

1.Nogueira LS, Zancanaro PC, Azambuja RD. Vitiligo and emotions. An Bras Dermatol 2009;84:41-5.   Back to cited text no. 1      
2.Sehgal VN, Srivastava G. Vitiligo: Compendium of clinicoepidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149-56.  Back to cited text no. 2  [PUBMED]  Medknow Journal  
3.Satish DA, Walia A. Epidemiology and etiopathogenesis. In: Saraf V, Fernandez R, Sarangi K, editors. Vitiligo. 1 st ed. Mumbai: Fulford India Ltd; 2000. p. 18-22.  Back to cited text no. 3      
4.Song MS, Hann SK, Ahn PS, Im S, Park YK. Clinical study of vitiligo:Comparative study of type A and B vitiligo. Ann Dermatol 1994;6:22-30.  Back to cited text no. 4      
5.Njoo MD, Westerhof W. Vitiligo: Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-81.  Back to cited text no. 5      
6.Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051-76.  Back to cited text no. 6      
7.Lotti T, Gori A, Zanieri F, Colucci R, Moretti S. Vitiligo: new and emerging treatments. Dermatol Ther 2008;21:110-7.  Back to cited text no. 7      
8.Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009;79:135-40.  Back to cited text no. 8      
9.Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008;22:1359-64.  Back to cited text no. 9      
10.Godse KV. Comparison of two diluents of 1% methoxsalen in the treatment of vitiligo. Indian J Dermatol Venereol Leprol 2008;74:298-9.   Back to cited text no. 10    Medknow Journal  
11.Kφster W, Wiskemann A. Phototherapy with UV-B in vitiligo. Z Hautkr 1990;65:1022-4.  Back to cited text no. 11      
12.Percivalle S, Piccino R, Caccialanza M, Forti S. Narrowband UVB phototherapy in vitiligo: evaluation of results in 53 patients. G Ital Dermatol Venereol 2008;143:9-14.  Back to cited text no. 12      
13.Abdulla SJ, Desgroseilliers JP. Treatment of vitiligo with narrow-band ultraviolet B: advantages and disadvantages. J Cutan Med Surg 2008;12:174-9.  Back to cited text no. 13      
14.Rodrνguez-Martνn M, Garcνa Bustνnduy M, Sαez Rodrνguez M, Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009;160:409-14.   Back to cited text no. 14      
15.Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev 2009;29:514-46.  Back to cited text no. 15      
16.Dusso AS, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis 1998;32:S13-24.  Back to cited text no. 16      
17.Boone B, Ongenae K, Van Geel N, Vernijns S, De Keyser S, Naeyaert JM. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007;17:55-61.  Back to cited text no. 17      
18.Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47:789-91.  Back to cited text no. 18      
19.Bentley MV, Vianna RF, Wilson S, Collett JH. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J Pharm Pharmacol 1997;49:397-402.  Back to cited text no. 19      
20.Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol 2009;26:286-91.  Back to cited text no. 20      
21.Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-68.  Back to cited text no. 21      
22.Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-9.  Back to cited text no. 22      
23.Tanioka M, Miyachi Y. Camouflage for vitiligo. Dermatol Ther 2009;22:90-3.   Back to cited text no. 23      
24.Hsu S. Camouflaging vitiligo with dihydroxyacetone. Dermatol Online J 2008;14:23.  Back to cited text no. 24      
25.Rajatanavin N, Suwanachote S, Kulkollakarn S. Dihydroxyacetone: a safe camouflaging option in vitiligo. Int J Dermatol 2008;47:402-6.   Back to cited text no. 25      
26.Idson B. Topical drug delivery: needs, theory and practice. Pharm Tech 1981;70:74-5.  Back to cited text no. 26      
27.Hadgraft J. Modulation of the barrier function of the skin. Skin Pharmacol Appl Skin Physiol 2001;14:72-81.  Back to cited text no. 27      
28.Roberts MS. Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease. Clin Exp Pharmacol Physiol 1997;24:874-9.   Back to cited text no. 28      
29.Kar PK, Snehi PS, Jha PK. Treatment of vitiligo with psoralen. Indian J Dermatol Venereol Leprol 1990;56:121-2.  Back to cited text no. 29    Medknow Journal  
30.Handa S, Pandhi R, Kaur I. Vitiligo: A retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol 2001;28:461-6.   Back to cited text no. 30      
31.Cross SE, Roberts MS. Physical enhancement of transdermal drug application: is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv 2004;1:81-92.  Back to cited text no. 31      
32.Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: Potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 2006;19:2-16.  Back to cited text no. 32      
33.Westesen K. Novel lipid-based colloidal dispersions as potential drug administration systems - expectations and reality. Colloid Polym Sci 2000;278:608-18.  Back to cited text no. 33      
34.Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004;56:675-711.  Back to cited text no. 34      
35.Valenta C, Wanka M, Heidlas J. Evaluation of novel soya-lecithin formulations for dermal use containing ketoprofen as a model drug. J Control Release 2000;63:165-73.  Back to cited text no. 35      
36.Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-33.  Back to cited text no. 36      
37.Sinico C, Valenti D, Manconi M, Lai F, Fadda AM. Cutaneous delivery of 8-methoxypsoralen from liposomal and niosomal carriers. J Drug Deliv Sci Technol 2006;16:115-20.  Back to cited text no. 37      
38.Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat 2007;18:40-5.  Back to cited text no. 38      
39.Manconia M, Pendαs J, Ledσn N, Moreira T, Sinico C, Saso L, et al. Phycocyanin liposomes for topical anti-inflammatory activity: in-vitro in-vivo studies. J Pharm Pharmacol 2009;61:423-30.  Back to cited text no. 39      
40.Jain B, Singh B, Katare OP, Vyas SP. Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res 2009 in press.   Back to cited text no. 40      
41.Singh HP, Utreja P, Tiwary AK, Jain S. Elastic liposomal formulation for sustained delivery of colchicine: in vitro characterization and in vivo evaluation of anti-gout activity. AAPS J 2009;11:54-64.  Back to cited text no. 41      
42.Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 2004;1663:61-73.  Back to cited text no. 42      
43.Fesq H, Lehmann J, Kontny A, Erdmann I, Theiling K, Rother M, et al. Improved risk-benefit ratio for topical triamcinolone acetonide in transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. Br J Dermatol 2003;149:11-9.  Back to cited text no. 43      
44.Fang YP, Tsai YH, Wu PC, Huang YB. Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm 2008;356:144-52.   Back to cited text no. 44      
45.Rao Y, Zheng F, Zhang X, Gao J, Liang W. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech 2008;9:860-5.  Back to cited text no. 45      
46.Maestrelli F, Capasso G, Gonzalez-Rodriguez ML, Rabasco AM, Ghelardini C, Mura P. Effect of preparation technique on the properties and in vivo efficacy of benzocaine-loaded ethosomes. J Liposome Res 2009;4:1-8.  Back to cited text no. 46      
47.Changez M, Varshney M, Chander J, Dinda AK. Effect of the composition of lecithin/n-propanol/isopropyl myristate/water microemulsions on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: in vitro. Colloids Surf B Biointerfaces 2006;50:18-25.   Back to cited text no. 47      
48.Fang JY, Leu YL, Chang CC, Lin CH, Tsai YH. Lipid nano/submicron emulsions as vehicles for topical flurbiprofen delivery. Drug Deliv 2004;11:97-105.  Back to cited text no. 48      
49.Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, et al. A study of microemulsion systems for transdermal delivery of triptolide. J Control Release 2004;98:427-36.  Back to cited text no. 49      
50.Liu H, Wang Y, Han F, Yao H, Li S. Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of cyclosporin A in vitro and dermal pharmacokinetics in vivo. J Pharm Sci 2007;96:3000-9.  Back to cited text no. 50      
51.Shaikh IM, Jadhav KR, Gide PS, Kadam VJ, Pisal SS. Topical delivery of aceclofenac from lecithin organogels: preformulation study. Curr Drug Deliv 2006;3:417-27.  Back to cited text no. 51      
52.Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009;10:289-96.   Back to cited text no. 52      
53.Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006;110:296-306.  Back to cited text no. 53      
54.Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008;70:633-40.  Back to cited text no. 54      



 
 
    Tables

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Nanosized ethosomes-based hydrogel formulations of methoxsalen for enhanced topical delivery against vitiligo: formulation optimization,in vitroevaluation and preclinical assessment
Bhawna Jain Garg,Neeraj K. Garg,Sarwar Beg,Bhupinder Singh,Om Prakash Katare
Journal of Drug Targeting. 2016; 24(3): 233
[Pubmed] | [DOI]
2 Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo Part II: Rheological characterization and in vivo assessment through dermatopharmacokinetic and pilot clinical studies
Hetal K. Patel,Bhavesh S. Barot,Punit B. Parejiya,Pragna K. Shelat,Arunkumar Shukla
Colloids and Surfaces B: Biointerfaces. 2014;
[Pubmed] | [DOI]
3 Comprehensive review on additives of topical dosage forms for drug delivery
Tarun Garg,Goutam Rath,Amit K. Goyal
Drug Delivery. 2014; : 1
[Pubmed] | [DOI]
4 Topical delivery of clobetasol propionate loaded microemulsion based gel for effective treatment of vitiligo: Ex vivo permeation and skin irritation studies
Hetal K. Patel,Bhavesh S. Barot,Punit B. Parejiya,Pragna K. Shelat,Arunkumar Shukla
Colloids and Surfaces B: Biointerfaces. 2013; 102: 86
[Pubmed] | [DOI]
5 Niosomes as a propitious carrier for topical drug delivery
Hamed Hamishehkar,Yahya Rahimpour,Maryam Kouhsoltani
Expert Opinion on Drug Delivery. 2013; 10(2): 261
[Pubmed] | [DOI]
6 Lecithin organogel: A unique micellar system for the delivery of bioactive agents in the treatment of skin aging
Sushil Raut,Santosh Singh Bhadoriya,Vaibhav Uplanchiwar,Vijay Mishra,Avinash Gahane,Sunil Kumar Jain
Acta Pharmaceutica Sinica B. 2012; 2(1): 8
[Pubmed] | [DOI]
7 Recent advances in various emerging vescicular systems: An overview
Mayank Gangwar,Ragini Singh,RK Goel,Gopal Nath
Asian Pacific Journal of Tropical Biomedicine. 2012; 2(2): S1176
[Pubmed] | [DOI]
8 Epidemiological profile and treatment pattern of vitiligo in a tertiary care teaching hospital
Reghu, R., James, E.
International Journal of Pharmacy and Pharmaceutical Sciences. 2011; 3(sup 2): 137-141
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow